Nuvalent Expands Leadership in Precision Lung Cancer
CAMBRIDGE, Mass., May 27, 2026 Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on developing precisely targeted cancer therapies, has...
lung cancer
Advertisement
Dizal Advances ZEGFROVY for EGFR Lung Cancer
SHANGHAI, China, May 27, 2026 Dizal, a biopharmaceutical company focused on developing targeted oncology therapies, has announced that China’s...
Foundation Medicine Wins FDA Approval for FoundationOne CDx in NSCLC
Boston, Massachusetts, USA, May 21, 2026 Foundation Medicine has announced that the U.S. Food and Drug Administration (FDA) has...
Henlius Wins CHMP Support for Serplulimab in Lung Cancer
Shanghai, China, May 23, 2026 Henlius Biotech has announced that the Committee for Medicinal Products for Human Use (CHMP)...
Ellipses Pharma and Kelun-Biotech Present EP0031 Data at ASCO 2026
LONDON, May 22, 2026 Ellipses Pharma and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that pivotal Phase 2 clinical trial...
Advertisements
Innovent’s IBI363 Shows Strong First-Line NSCLC Data
SAN FRANCISCO and SUZHOU, China, May 22, 2026 Innovent Biologics announced encouraging preliminary Proof-of-Concept (PoC) clinical data for IBI363,...
Innovent IBI363 Shows Strong Survival in NSCLC
SAN FRANCISCO and SUZHOU, China, May 21, 2026 Innovent Biologics, Inc. announced updated long-term clinical data from the Phase...
Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...
Bayer’s Asundexian Wins FDA Priority Review
BERLIN, Germany, May 19, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) and Japan’s Ministry...
Curia Upgrades Spain API Suites for EU GMP Annex 1
ALBANY, N.Y., May 19, 2026 Curia Global, Inc. has announced the completion of a major upgrade to its aseptic...
Advertisement
